Systems analysis of real-world obstacles to successful cervical cancer prevention in developing countries

American Journal of Public Health

Volumn 96, Issue 3, 2006, Pages 480-487

  Suba, Eric J ^a   Murphy, Sean K ^b   Donnelly, Amber D ^c   Furia, Lisa M ^d   Huynh, Linh D ^e   Raab, Stephen S ^f  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b Valence Point Group   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PREVENTION; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL LABORATORY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; FEMALE; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VACCINE PRODUCTION; WART VIRUS;

DEVELOPING COUNTRIES; FEMALE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; MASS SCREENING; PUBLIC HEALTH PRACTICE; SYSTEMS THEORY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; WOMEN'S HEALTH SERVICES;

EID: 33644612859     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2004.061606     Document Type: Article

References (85)

1. Callahan D. False Hopes: America's Quest for Perfect Health Is a Recipe for Failure. New York: Simon & Schuster; 1999.
2. World Health Organization. World report on knowledge for better health. Available at: http://www.who.int/rpc/ meetings/wr2004/en/. Accessed August 30, 2005.
3. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002; 97:72-81.
4. Feachem R, Kjellstrom T, Murray C, Over M, Phillips M, eds. The Health of Adults in the Developing World. New York, NY: Oxford University Press Inc; 1992.
5. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine. 1999;17: 646-652.
6. Sherman ME, Schiffman MH, Strickler H, Hildesheim A. Prospects for a prophylactic HPV vaccine: rationale and future implications for cervical cancer screening. Diagn Cytopathol. 1998; 18:5-9.
7. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290:781-789.
8. Agency for Healthcare Research and Quality. Screening for cervical cancer: file inventory. Available at: http:// www.ncbi.nlm.nih.gov/books/bv. fcgi? rid=hstat3.section.4193. Accessed August 30, 2005.
9. Suba EJ, Raab SS, Viet/American Cervical Cancer Prevention Project. Papanicolaou screening in developing countries: an idea whose time has come. Am J Clin Pathol. 2004;121: 315-320.
10. Suba EJ, Raab SS, Viet/American Cervical Cancer Prevention Project. Pap screening in developing countries: an idea whose time has come [author reply]. Am J Clin Pathol 2005;124(2): 315-316
11. Cuzick J. Screening for cancer: future potential. Eur J Cancer. 1999;35: 685-692.
12. Cronje HS. Screening for cervical cancer in developing countries. Int J Gynaecol Obstet. 2004;84:101-108.
13. Handbook of Cancer Prevention, Volume 10: Cervix Cancer Screening. Lyon, France: International Agency for Research on Cancer; 2005.
14. Tay EH. Pap smear screening for cervical cancer in Singapore: issues to consider. Singapore Med J. 2004;45: 244-246.
15. Lazcano-Ponce EC, Moss S, Alonso de Ruiz P, Salmeron Castro J, Hernandez Avila M. Cervical cancer screening in developing countries: why is it ineffective? The case of Mexico. Arch Med Res. 1999;30:240-250.
16. Miller AB. Quality assurance in screening strategies. Virus Res. 2002; 89:295-299.
17. Ponten J, Adami HO, Bergstrom R, et al. Strategies for global control of cervical cancer. Int J Cancer. 1995;60: 1-26.
18. Suba EJ, Viet/American Cervical Cancer Prevention Project. Crossing the quality chasm: a requirement for successful cervical cancer prevention in developing countries. Clin Lab Med. 2004; 24:945-963.
19. Huynh MLD, Raab SS, Suba EJ. Association between war and cervical cancer among Vietnamese women. Int J Cancer. 2004;110:775-777.
20. Suba EJ, Donnelly AD, Furia LM, Huynh MLD, Raab SS, Viel/American Cervical Cancer Prevention Project. Coming to terms with Vietnam: the Wet/American Cervical Cancer Prevention Project. Diagn Cytopathol. 2005; 33:344-351.
21. Suba EJ, Hung NC, Due NB, Raab SS, Viet/American Cervical Cancer Prevention Project. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam. Cancer. 2001;91:928-939.
22. Raab SS. Cost-effectiveness analysis in pathology. Clin Lab Med. 1999;19: 757-771.
23. Levin CE, Sellors JW. De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam [letter]. Cancer. 2002;94: 2312-2314.
24. Pollack AE, Tsu VD. Preventing cervical cancer in low-resource settings: building a case for the possible. Int J Gynaecol Obstet. 2005;89(suppl 2): S1-S3.
25. Chassin MR, Hannan EL, DeBuono BA. Benefits and hazards of reporting medical outcomes publicly. N Engl J Med. 1996;334:394-398.
26. Institute of Medicine. Measuring the Quality of Health Care. Washington, DC: National Academy Press; 1999.
27. Ohno T. Toyota Production System: Beyond Large-Scale Production. Portland, Ore: Productivity Press; 1988.
28. Battles JB, Kaplan HS, Van der Schaaf TW, Shea CE. The attributes of medical event-reporting systems: experience with a prototype medical event-reporting system for transfusion medicine. Arch Pathol Lab Med. 1998;122: 231-238.
29. US Veterans Administration, National Center for Patient Safety. Root cause analysis. Available at: http:// www.patientsafety.gov/rca.html. Accessed August 30, 2005.
30. Condel JL, Sharbaugh DT, Raab SS. Error-free pathology: applying lean production methods to anatomic pathology. Clin Lab Med. 2004;24:865-899.
31. Geisinger KR. Obstacles to reducing cervical cancer in Vietnam. Am J Clin Pathol. 2004;121:313-314.
32. Quoc NM, Hung NC, Parkin DM. Cancer incidence in Ho Chi Minh City, Vietnam, 1995-1996. Int J Cancer. 1998;76:472-479.
33. Hoang Anh PT, Parkin DM, Hanh NT, Due NB. Cancer in the population of Hanoi, Vietnam, 1988-1990. Br J Cancer. 1993;68:1236-1242.
34. Hoang Anh PT, Hieu NT, Herrero R, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer. 2003; 104:213-220.
35. World Health Organization. Cervical cancer screening in developing countries: report of a WHO consultation. Available at: http://www.who.int/ reproductive-health/cancers/cervical_ cancer_screening_in_dev_countries.pdf. Accessed August 30, 2005.
36. Lazcano-Ponce EC, Alonso de Ruiz P, Lopez-Carrillo L, et al. Validity and reproducibility of cytologic diagnosis in a sample of cervical cancer screening centers in Mexico. Acta Cytol. 1997;41: 277-284.
37. Bogdanich W. Lax laboratories: the Pap test misses much cervical cancer through labs' errors. Wall Street Journal. November 2, 1987:1.
38. Flisser A, Garcia-Malo F, Canepa M, et al. Implementation and evaluation of a national external quality control program for cervical cytology in Mexico. Salud Publica Mex. 2002;44: 431-436.
39. Wang L. Developing countries put cervical cancer tests to the test. J Natl Cancer Inst. 2002;94: 245-247.
40. Robyr R, Nazeer S, Vassilakos P, et al. Feasibility of cytology-based cervical cancer screening in rural Cameroon. Acta Cytol. 2002;46:1110-1116.
41. Belinson JL, Qiao Y, Pretorius R, et al. Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. Int J Gynecol Cancer. 1999;9: 411-417.
42. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439-444.
43. Schiffman M, Herrero R, Hildesheim A, et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA. 2000;283:87-93.
44. Wright TC Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA. 2000;283: 81-86.
45. Richart RM, Sankaranarayanan R, Robles S, Wright TC Jr. Cervical cancer screening strategies for developing countries. Contemp Ob/Gyn. January 2001:71-79, 100-127.
46. University of Zimbabwe/JHPIEGO Cervical Cancer Project. Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary care setting. Lancet 1999;353: 869-873.
47. Wright TC Jr, Denny L, Kuhn L, Goldie S. Use of visual screening methods for cervical cancer screening. Obstet Gynecol Clin North Am. 2002;29: 701-734.
48. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC Jr. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer. 2000;89:826-833.
49. Lewis M. Situational Analysis of Cervical Cancer in Latin America and the Caribbean. Washington, DC: Pan American Health Organization; 2004.
50. Nguyen TH, Nguyen TL, Trinh QH. HIV/AIDS epidemics in Vietnam: evolution and responses. AIDS Educ Prev. 2004;16(suppl A):137-154.
51. Zeitlin GA, Maslow MJ. Avian influenza. Curr Infect Dis Rep. 2005;7: 193-199.
52. Birn AE. Gates's grandest challenge: transcending technology as public health ideology. Lancet. 2005;366: 514-519.
53. Revealed: how stars were hijacked to boost health company's profits. Available at: http://observer.guardian.co.uk/ uk_news/story/0,6903,1130785,00. html. Accessed August 30, 2005.
54. Sankaranarayanan R, Gaffikin L, Jacob M, Sellors J, Robles S. A critical assessment of screening methods for cervical neoplasia. Int J Gynaecol Obstet. 2005;89(suppl 2)54-812.
55. Ministry of Health, Republic of South Africa. National guideline on cervical cancer screening program. Available at: http://www.doh.gov.za/ docs/index.html. Accessed August 30, 2005.
56. Suba EJ, Raab SS, Viet/American Cervical Cancer Prevention Project. Real-world obstacles to successful cervical cancer prevention in developing countries. Cytopathology. 2005; 16(suppl 1):5-6.
57. Frumkin P, Chetkovich C. Balancing margin and mission: nonprofit competition in charitable versus fee-based programs. Available at: http://ssrn.com/ abstract=351221. Accessed August 30, 2005.
58. Robles SC, Periago MR. Guanacaste, Costa Rica: a landmark for cervical cancer prevention. Rev Panam Salud Publica. 2004;15:73-74.
59. Herrero R, Schiffman MH, Hildesheim A, et al. Is cervical cancer cytological screening valuable in developing countries? In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford, England: Blackwell Sciences Ltd; 1997:241-249.
60. Hutchinson ML, Zahniser DJ, Sherman ME, et al. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer. 1999;87: 48-55.
61. Herrero R, Schiffman MH, Bratti C, et al. Evaluation of multiple screening techniques in a high-risk area: the Guanacaste Project. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Oxford, England: Blackwell Sciences Ltd; 1997: 389-399.
62. Schneider DL, Herrero R, Bratti C, et al. Cervicography screening for cervical cancer among 8460 women in a high-risk population. Am J Obstet Gynecol. 1999;180:290-298.
63. Sherman ME, Schiffman M, Herrero R, et al. Performance of a semiautomated Papanicolaou smear screening system: results of a population-based study conducted in Guanacaste, Costa Rica. Cancer. 1998;84:273-280.
64. Hartmann KE, Nanda K, Hall S, Myers E. Technologic advances for evaluation of cervical cytology: is newer better? Obstet Gynecol Surv. 2001;56: 765-774.
65. Sawaya GF, Grimes DA. New technologies in cervical cytology screening: a word of caution. Obstet Gynecol 1999; 94:307-310.
66. Koss LG. Utility of liquid-based cytology for cervical carcinoma screening. Cancer. 2000;90:67-69.
67. Patnick J. Cervical cancer screening in England. Eur J Cancer. 2000;36: 2205-2208.
68. Stjernsward J, Eddy D, Luthra U, Stanley K. Plotting a new course for cervical cancer screening in developing countries. World Health Forum. 1987;8: 42-45.
69. Prisoner's dilemma. Available at: http://plato.stanford.edu/entries/ prisoner-dilemma/. Accessed August 30, 2005.
70. To DA, Bui D. Current status of radiotherapy in Vietnam, 2002. Radiat Med. 2004;22:12-16.
71. Sankaranarayanan R, Nene BM, Dinshaw K, et al. Early detection of cervical cancer with visual inspection methods: a summary of completed and on-going studies in India. Salud Publica Mex. 2003;45(suppl 3):S399-S407.
72. Thomas SB, Quinn SC. The Tuskegee Syphilis Study, 1932 to 1972: implications for HIV education and AIDS risk education programs in the black community. Am J Public Health. 1991;81:1498-1505.
73. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med. 1999;14:537-546.
74. Sankaranarayanan R, Nene BM, Dinshaw KA, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer. 2005;116: 617-623.
75. Womack SD, Chirenje ZM, Blumenthal PD, et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG. 2000; 107:33-38.
76. Sankaranarayanan R, Chatterji R, Shastri SS, et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. Int J Cancer. 2004;112:341-347.
77. Sankaranarayanan R, Thara S, Sharma A, et al. Accuracy of conventional cytology: results from a multicentre screening study in India. J Med Screen. 2004;11:77-84.
78. Cervical cancer largely preventable. Available at: http://www.usatoday. com/news/health/2004-12-16-who-cancer_x.htm. Accessed August 30, 2005.
79. Kornegay JR, Roger M, Davies PO, et al. International proficiency study of a consensus L1 PCR assay for the detection and typing of human papillomavirus DNA: evaluation of accuracy and intralaboratory and interlaboratory agreement. J Clin Microbiol. 2003;41: 1080-1086.
80. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
81. Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med. 2000;124:672-681.
82. Suba EJ, Raab SS. Direct visual inspection for cervical cancer screening [letter]. Cancer. 2004;101: 2365-2366.
83. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005; 353:2158-2168.
84. American College of Obstetrics and Gynecology. ACOG statement of policy: cervical cancer prevention in low-resource settings. Obstet Gynecol. 2004;103:607-608.
85. Appalachia Leadership Initiative on Cancer. Sowing Seeds in the Mountains: Community-Based Coalitions for Cancer Prevention and Control. Bethesda, Md: National Cancer Institute; 1994:1. NIH publication 94-3779.